Comparative analysis of inflamed and non-inflamed colon biopsies reveals strong proteomic inflammation profile in patients with ulcerative colitis

BMC Gastroenterology

Lotte Bach Larsen²  Stig Purup⁴  Flemming Jessen⁵  Hanne Søndergaard Møller²  Jens Christian Møller³  Vibeke Andersen¹  Nina Aagaard Poulsen² 

[1] Institute of Regional Health Services Research, South Danish University, Odense 5000, Denmark;Department of Food Science, Aarhus University, Tjele 8830, Denmark;Pathological Department, Viborg Regional Hospital, Viborg 8800, Denmark;Department of Animal Science, Aarhus University, Tjele 8830, Denmark;National Food Institute, Technical University of Denmark, 2800 Kgs Lyngby, Denmark

关键词: MS-based proteomics;    Candidate markers;    Colon biopsies;    Ulcerative colitis;    Inflammatory bowel disease;   

Others  :  1113030
DOI  :  10.1186/1471-230X-12-76

 received in 2012-02-16, accepted in 2012-06-15,  发布年份 2012

【 摘 要 】

Background

Accurate diagnostic and monitoring tools for ulcerative colitis (UC) are missing. Our aim was to describe the proteomic profile of UC and search for markers associated with disease exacerbation. Therefore, we aimed to characterize specific proteins associated with inflamed colon mucosa from patients with acute UC using mass spectrometry-based proteomic analysis.

Methods

Biopsies were sampled from rectum, sigmoid colon and left colonic flexure from twenty patients with active proctosigmoiditis and from four healthy controls for proteomics and histology. Proteomic profiles of whole colonic biopsies were characterized using 2D-gel electrophoresis, and peptide mass fingerprinting using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was applied for identification of differently expressed protein spots.

Results

A total of 597 spots were annotated by image analysis and 222 of these had a statistically different protein level between inflamed and non-inflamed tissue in the patient group. Principal component analysis clearly grouped non-inflamed samples separately from the inflamed samples indicating that the proteomic signature of colon mucosa with acute UC is strong. Totally, 43 individual protein spots were identified, including proteins involved in energy metabolism (triosephosphate isomerase, glycerol-3-phosphate-dehydrogenase, alpha enolase and L-lactate dehydrogenase B-chain) and in oxidative stress (superoxide dismutase, thioredoxins and selenium binding protein).

Conclusions

A distinct proteomic profile of inflamed tissue in UC patients was found. Specific proteins involved in energy metabolism and oxidative stress were identified as potential candidate markers for UC.

【 授权许可】

   
2012 Poulsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, Nielsen GL, Sorensen HT: Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002. Eur J Gastroenterol Hepatol 2006, 18:601-606.
• [2]Thompson AI, Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis 2011, 17:831-848.
• [3]Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagace C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RSN, Floyd JAB, Florin T, Franchimont D, et al.: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252.
• [4]Andersen V, Ernst A, Christensen J, Ostergaard M, Jacobsen B, Tjonneland A, Krarup H, Vogel U: The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case–control study. BMC Med Genet 2010, 11:82.
• [5]Andersen V, Nimmo E, Krarup HB, Drummond H, Christensen J, Ho GT, Ostergaard M, Ernst A, Lees C, Jacobsen BA, Satsangi J, Vogel U: Cyclooxygenase-2 (COX-2) Polymorphisms and Risk of Inflammatory Bowel Disease in a Scottish and Danish Case–control Study. Inflamm Bowel Dis 2011, 17:937-946.
• [6]Andersen V, Christensen J, Ernst A, Jacobsen BA, Tjonneland A, Krarup HB, Vogel U: Polymorphisms in NF-kappa B, PXR, LXR, PPAR gamma and risk of inflammatory bowel disease. World J Gastroenterol 2011, 17:197-206.
• [7]Baumgart DC, Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
• [8]Alex P, Gucek M, Li XH: Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies. Inflamm Bowel Dis 2009, 15:616-629.
• [9]Werner T, Haller D: Intestinal epithelial cell signalling and chronic inflammation: From the proteome to specific molecular mechanisms. Mutat Res 2007, 622:42-57.
• [10]Kok K, Stokkers P, Reitsma PH: Genomics and proteomics - Implications for inflammatory bowel diseases. Inflamm Bowel Dis 2004, 10:S1-S6.
• [11]Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, Belluzzi A, Mayer L, Roda A: New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:1239-1246.
• [12]Din S, Lennon AM, Arnott ID, Hupp T, Satsangi J: Technology insight: the application of proteomics in gastrointestinal disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:372-385.
• [13]Nanni P, Parisi D, Roda G, Casale M, Belluzzi A, Roda E, Mayer L, Roda A: Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom 2007, 21:4142-4148.
• [14]Meuwis MA, Fillet M, Chapelle JP, Malaise M, Louis E, Merville MP: New biomarkers of Crohn´s disease: serum biomarkers and development of diagnostic tools. Expert Rev Mol Diagn 2008, 8:327-337.
• [15]Meuwis MA, Fillet M, Geurts P, de Seny D, Lutteri L, Chapelle JP, Bours V, Wehenkel L, Belaiche J, Malaise M, Louis E, Merville MP: Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007, 73:1422-1433.
• [16]Li XH, Conklin L, Alex P: New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008, 14:5115-5124.
• [17]Kanmura S, Uto H, Numata M, Hashimoto S, Moriuchi A, Fujita H, Oketani M, Ido A, Kodama M, Ohi H, Tsubouchi H: Human Neutrophil peptides 1–3 are useful biomarkers in patients with active ulcerative colitis. Inflamm Bowel Dis 2009, 15:909-917.
• [18]Von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson JO, Sundberg R, Hellstrom K, Eriksson A, Befrits R, Ost A, Von Stein OD: Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology 2008, 134:1869-1881.
• [19]Shkoda A, Werner T, Daniel H, Gunckel M, Rogler G, Haller D: Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res 2007, 6:1114-1125.
• [20]Comelli EM, Lariani S, Zwahlen MC, Fotopoulos G, Holzwarth JA, Cherbut C, Dorta G, Corthesy-Theulaz I, Grigorov M: Biomarkers of human gastrointestinal tract regions. Mamm Genome 2009, 20:516-527.
• [21]Wu F, Dassopoulos T, Cope L, Maitra A, Brant SR, Harris ML, Bayless TM, Parmigiani G, Chakravarti S: Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: Insights into distinctive pathogenesis. Inflamm Bowel Dis 2007, 13:807-821.
• [22]Hsieh SY, Shih TC, Yeh CY, Lin CJ, Chou YY, Lee YS: Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006, 6:5322-5331.
• [23]Mendoza JL, Abreu MT: Biological markers in inflammatory bowel disease: Practical consideration for clinicians. Gastroenterol Clin Biol 2009, 33:S158-S173.
• [24]Lopes LV, Kussmann M: Proteomics at the interface of phychology, gut physiology and dysfunction: an underexploited approach that deserves expansion. Expert Rev Proteomics 2011, 8:605-614.
• [25]Vatn M: Natural history and complications of IBD. Curr Gastroenterol Rep 2009, 11:481-487.
• [26]Lewis JD: The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. Gastroenterology 2011, 140:1817-1826.
• [27]Podolsky DK: Inflammatory Bowel Disease. N Engl J Med 2002, 347:417-429.
• [28]Geboes K, Riddell R, Öst A, Jensfelt B, Persson T, Löfberg R: A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47:404-409.
• [29]Day DW, Jass JR, Price AB, Shepherd NA, Sloan JM, Talbot IC, Warren BF, Williams GT: Inflammatory disorders of the large intestine. Morson and Dawson's Gastrointestinal Pathology. Blackwell Science Ltd, In; 2003:472-539.
• [30]Jensen ON, Larsen MR, Roepstorff P: Mass spectrometric identification and microcharacterization of proteins from electrophoretic gels: Strategies and applications. Proteins 1998, 2:74-89.
• [31]Lametsch R, Roepstorff P, Bendixen E: Identification of protein degradation during post-mortem storage of pig meat. J Agric Food Chem 2002, 50:5508-5512.
• [32]Storey JD: A direct approach to false discovery rates. J R Stat Soc B 2002, 64:479-498.
• [33]Jensen KN, Jessen F, Jorgensen BM: Multivariate data analysis of two-dimensional gel electrophoresis protein patterns from few samples. J Proteome Res 2008, 7:1288-1296.
• [34]Turroni S, Vitali B, Candela M, Gionchetti P, Rizzello F, Campieri M, Brigidi P: Antibiotics and probiotics in chronic pouchitis: A comparative proteomic approach. World J Gastroenterol 2010, 16:30-41.
• [35]Nanni P, Mezzanotte L, Roda G, Caponi A, Levander F, James P, Roda A: Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry. J Proteomics 2009, 72:865-873.
• [36]Roediger WEW: The colonic epithelium in Ulcerative-Colitis - An Energy-Deficiency Disease. Lancet 1980, 2:712-715.
• [37]Vermeulen N, Arijs I, Joossens S, Vermeire S, Clerens S, Van den Bergh K, Michiels G, Arckens L, Schuit F, Van Lommel L, Rutgeerts P, Bossuyt X: Anti-alpha-enolase antibodies in patients with inflammatory bowel disease. Clin Chem 2008, 54:534-541.
• [38]Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW: Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 1995, 270:27752-27757.
• [39]Ludwig D, Stahl M, Ibrahim ME, Wenzel BE, Drabicki D, Wecke A, Fellermann K, Stange EF: Enhanced intestinal expression of heat shock protein 70 in patients with inflammatory bowel diseases. Dig Dis Sci 1999, 44:1440-1447.
• [40]Winrow VR, Mojdehi GM, Ryder SD, Rhodes JM, Blake DR, Rampton DS: Stress Proteins in Colorectal Mucosa - Enhanced Expression in Ulcerative-Colitis. Dig Dis Sci 1993, 38:1994-2000.
• [41]Araki K, Mikami T, Yoshida T, Kikuchi M, Sato Y, Oh-ishi M, Kodera Y, Maeda T, Okayasu I: High expression of HSP47 in ulcerative colitis-associated carcinomas: proteomic approach. Br J Cancer 2009, 101:492-497.
• [42]Kruidenier L, Verspaget HW: Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment Pharmacol Ther 2002, 16:1997-2015.
• [43]Kruidenier L, Kuiper I, van Duijn W, Mieremet-Ooms MAC, van Hogezand RA, Lamers CBHW, Verspaget HW: Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 2003, 201:17-27.
• [44]LihBrody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ, Fisher SE, Mullin GE: Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996, 41:2078-2086.
• [45]Kruidenier L, Kuiper I, van Duijn W, Marklund SL, van Hogezand RA, Lamers CBHW, Verspaget HW: Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol 2003, 201:7-16.
• [46]Dagli U, Balk M, Yucel D, Ulker A, Over H, Saydam G, Sahin B: The role of reactive oxygen metabolites in ulcerative colitis. Inflamm Bowel Dis 1997, 3:260-264.
• [47]Polley ACJ, Mulholland F, Pin C, Williams EA, Bradburn DM, Mills SJ, Mathers JC, Johnson IT: Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia. Cancer Res 2006, 66:6553-6562.
• [48]Mann M, Jensen ON: Proteomic analysis of post-translational modifications. Nat Biotechnol 2003, 21:255-261.
• [49]Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield E, Potapova O, Riegman P, Rubenstein Y, Seijo E, Somiari Sm, Watson P, Weier H, Zhu C, Vaught J: Biospecimen reporting for improved study quality (BRISQ). J Proteome Res 2011, 10:3429-3438.